In a move that signals the rising prominence of generic drug-making in today's marketplace, major generic pharmaceutical company Teva Pharmaceutical Industries recently announced its plans to acquire another generic drug-making conglomerate, SICOR.
The landmark transaction, which bears a price tag of around $3.4 billion, translates to about $1 billion in financing needed from the debt markets, and market constituents contend that the deal might trigger a wave of more consolidations in the sector, including the generic pharmaceutical space.
This transaction will spark more market activity, said one analyst who covers Teva. With more activity, companies in the sector could access the …
No comments:
Post a Comment